View Older Stories View More Recent Stories

Nov 12, 2020 05:25PM VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress
Nov 12, 2020 08:30AM VistaGen Reports Positive Preclinical Data Differentiating Mechanism of Action of PH94B from Risk-Ridden Benzodiazepines
Nov 9, 2020 08:00AM VistaGen Therapeutics to Participate in the Guggenheim Healthcare Talks | Idea Forum | 2nd Annual Neuro/Immunology Day
Oct 14, 2020 08:34AM VistaGen Therapeutics (VTGN) Announces Nasdaq Grants it 180-Day Extension to Meet Minimum Bid Price Requirement
Oct 14, 2020 08:30AM Nasdaq Grants VistaGen 180-Day Extension to Meet Minimum Bid Price Requirement
Sep 3, 2020 08:35AM VistaGen Therapeutics (VTGN) Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid
Sep 3, 2020 08:30AM VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid
Aug 27, 2020 08:30AM VistaGen Therapeutics to Present at the LD Micro 500 Virtual Conference
Aug 13, 2020 04:30PM VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
Aug 10, 2020 08:30AM VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering
Aug 5, 2020 04:30PM VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public Offering
Aug 4, 2020 08:04AM VistaGen Therapeutics (VTGN) Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration
Aug 4, 2020 08:00AM VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration
Aug 3, 2020 05:49AM VistaGen Therapeutics (VTGN) Prices 15.625M Share Common Offering at $0.80/Sh
Aug 2, 2020 08:00PM VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock
Jul 31, 2020 04:18PM VistaGen Therapeutics Announces Proposed Public Offering of Common Stock
Jul 23, 2020 08:06AM VistaGen Therapeutics (VTGN) Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder
Jul 23, 2020 08:00AM VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder
Jun 29, 2020 05:16PM VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
Jun 25, 2020 08:08AM VistaGen Therapeutics (VTGN), EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia
Jun 25, 2020 08:00AM VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia
May 27, 2020 08:11AM VistaGen (VTGN), Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
May 27, 2020 08:00AM VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
May 18, 2020 08:06AM VistaGen Therapeutics (VTGN) Reports FDA CTAP Submission of PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to COVID-19 Pandemic
May 18, 2020 08:05AM VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
Apr 28, 2020 09:17AM VistaGen Therapeutics (VTGN) Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19
Apr 28, 2020 09:15AM VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19
Mar 25, 2020 09:08AM VistaGen Therapeutics (VTGN) Reports Purchase Agreement with Lincoln Park Capital Fund up to $10.25M
Mar 25, 2020 09:00AM VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
Feb 20, 2020 08:39AM VistaGen Therapeutics (VTGN) Reports Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of MDD
Feb 20, 2020 08:30AM VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder
Feb 13, 2020 04:30PM VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
Feb 11, 2020 08:39AM VistaGen Therapeutics (VTGN) Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects
Feb 11, 2020 08:30AM VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects
Jan 30, 2020 08:37AM VistaGen Therapeutics (VTGN) Granted FDA Clearance of IND for Phase 2 Clinical Study of AV-101
Jan 30, 2020 08:30AM VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients
Dec 19, 2019 08:36AM VistaGen (VTGN), Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with AV-101 Focused on Treating Suicidal Ideation in Veterans
Dec 19, 2019 08:30AM VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans
Dec 10, 2019 08:32AM VistaGen Therapeutics (VTGN) Granted FDA Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
Dec 10, 2019 08:30AM U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
Nov 14, 2019 07:36AM VistaGen Therapeutics (VTGN) Says AV-101 as Adjunctive Treatment of MDD Did not Differentiate from Placebo on Primary Endpoint in Phase 2 Study
Nov 14, 2019 07:30AM VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
Nov 7, 2019 06:30AM VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
Oct 28, 2019 08:43AM VistaGen Therapeutics (VTGN) Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
Oct 28, 2019 08:30AM VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
Oct 8, 2019 08:36AM VistaGen Therapeutics (VTGN) Reports Last Patient Completes Dosing in ELEVATE Phase 2 Clinical Study of AV-101 for MDD
Oct 8, 2019 08:30AM VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder
Jul 23, 2019 08:40AM VistaGen Therapeutics (VTGN) Secures USPTO Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray
Jul 23, 2019 08:30AM VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray
Jun 25, 2019 04:15PM VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview
View More Recent Stories View Older Stories